Drug eluting stents: are human and animal studies comparable?
- 1Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington DC, USA
- 2Hôpital Européen Georges Pompidou, INSERM E00-16, Université, Paris V, France
- Correspondence to:
Dr Renu Virmani, Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, 6825 16th Street NW, Washington DC 20306-6000, USA;
- Accepted 22 September 2002
Animal models of stenting probably predict human responses as the stages of healing are remarkably similar. What is characteristically different is the temporal response to healing, which is substantially prolonged in humans. The prevention of restenosis in recent clinical trials of drug eluting stents may represent a near absent or incomplete phase of intimal healing. Continued long term follow up of patients with drug eluting stents for major adverse cardiac events and angiographic restenosis is therefore imperative.
- ASPECT, Asian paclitaxel eluting stent clinical trial
- ELUTES, evaluation of paclitaxel-eluting stent
- IVUS, intravascular ultrasound
- MACE, major adverse cardiac event
- RAVEL, randomised study with the sirolimus eluting velocity balloon expandable stent in treatment of de novo native coronary artery lesions
- SIRIUS, sirolimus eluting stent